About the Company

Medeia Therapeutics Ltd., founded in 2006, is a private biotechnology company dedicated to discover and develop completely new therapeutic approaches for diseases with high unmet medical needs.

Medeia’s focus areas include the discovery, preclinical research and early development of novel therapeutics. Our R&D programs aim at developing small molecules for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases.

Medeia operates under a semi-virtual business model- we outsource all non-core business functions while retaining seamless control over key technology assets, strategic partnerships and financial management with a small core group of highly experienced employees.